Folate Analog Metabolic Inhibitor

Lymphoma, T-Cell, Peripheral

<section class="Section" data-sectioncode="34089-3"><a name="s41"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Pralatrexate is a dihydrofolate reductase inhibitor. Pralatrexate has the chemical name (2S)-2-[[4-[(1RS)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3- ynyl]benzoyl]amino]pentanedioic acid. The molecular formula is C<span class="Sub">23</span>H<span class="Sub">23</span>N<span class="Sub">7</span>O<span class="Sub">5</span> and the molecular weight is 477.48 g/mol. Pralatrexate is a 1:1 racemic mixture of S- and R- diastereomers at the C10 position (indicated with *). The structural formula is as follows:</p><div class="Figure"><img alt="Structural Formula " src="image-01.jpg"/></div><p>   </p><p>Pralatrexate is an off-white to yellow solid. It is soluble in aqueous solutions at pH 6.5 or higher. Pralatrexate is practically insoluble in chloroform and ethanol. The pKa values are 3.25, 4.76, and 6.17.</p><p>FOLOTYN (pralatrexate) is supplied as a preservative-free, sterile, isotonic, non-pyrogenic clear yellow aqueous solution contained in a clear glass single-dose vial (Type I) for intravenous use. Each 1 mL of solution contains 20 mg of pralatrexate, sufficient sodium chloride to achieve an isotonic (280-300 mOsm) solution, and sufficient sodium hydroxide, and hydrochloric acid if needed, to adjust and maintain the pH at 7.5-8.5. FOLOTYN is supplied as either 20 mg (1 mL) or 40 mg (2 mL) single-dose vials at a concentration of 20 mg/mL.</p></section>

Folotyn

1 ML pralatrexate 20 MG/ML Injection

1 ML pralatrexate 20 MG/ML Injection [Folotyn]

2 ML pralatrexate 20 MG/ML Injection

2 ML pralatrexate 20 MG/ML Injection [Folotyn]

pralatrexate

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Submit MSL Request 

Pharmacy List 

Coding Guide 

STAR Patient Enrollment Form 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll in Patient Savings Program 

Patient Assistance Program 

About Folotyn 

Receiving Folotyn 

Side Effects 

Patient Resources 

Instructions For Use: Relapsed or Refractory PTCL 

Reimbursement Information

Prescribing Information

Medication Guide 